Items Per Page 102550 Year All20242023202220212020201920182017 March 11, 2024 ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients PDF Version March 6, 2024 ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors PDF Version February 29, 2024 ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat PDF Version January 2, 2024 ASLAN Pharmaceuticals Announces Participation in January Investor Conferences PDF Version December 12, 2023 ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs PDF Version November 20, 2023 ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference PDF Version November 3, 2023 ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit PDF Version October 27, 2023 ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update PDF Version October 24, 2023 ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis PDF Version October 18, 2023 ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis PDF Version
March 11, 2024 ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients PDF Version
March 6, 2024 ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors PDF Version
February 29, 2024 ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat PDF Version
January 2, 2024 ASLAN Pharmaceuticals Announces Participation in January Investor Conferences PDF Version
December 12, 2023 ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs PDF Version
November 20, 2023 ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference PDF Version
November 3, 2023 ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit PDF Version
October 27, 2023 ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update PDF Version
October 24, 2023 ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis PDF Version
October 18, 2023 ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis PDF Version